Boston Scientific To Report Q3 Results By Nov. 14 Despite Japan Difficulties
This article was originally published in The Gray Sheet
Executive Summary
The detection of $40-50 mil. in improperly recorded sales in 1998 by Boston Scientific's Japan subsidiary is bittersweet testimony to the effectiveness of the firm's recently installed corporate SAP computer system.
You may also be interested in...
Boston Scientific Settles With SEC On 1997/98 Japan Sales Irregularities
A settlement reached between Boston Scientific and the Securities and Exchange Commission in connection with improperly recorded sales by the company's Japanese operation does not include a fine.
Boston Scientific Settles With SEC On 1997/98 Japan Sales Irregularities
A settlement reached between Boston Scientific and the Securities and Exchange Commission in connection with improperly recorded sales by the company's Japanese operation does not include a fine.
Boston Scientific's Strong Japanese Sales Help Offset U.S., EU Declines
Emerging stent and balloon markets in Japan gave Boston Scientific its fourth consecutive quarter of market leadership in those businesses, as revenues grew 47% over the fourth quarter of 1998, the firm reported during a Feb. 8 teleconference.